Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)
China · Delayed Price · Currency is CNY 25.98
-0.49 (-1.85%)
At close: Sep 2, 2026
SHE:301258 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 388.74 | 427.18 | 426.01 | 483.1 | 548.95 | 511.66 |
Other Revenue | 5.55 | 5.55 | 3.46 | 6.19 | 19.26 | 10.03 |
| 394.29 | 432.73 | 429.47 | 489.29 | 568.21 | 521.7 | |
Revenue Growth | -9.72% | 0.76% | -12.23% | -13.89% | 8.92% | 9.40% |
Cost of Revenue | 334.43 | 358.09 | 348.04 | 301.22 | 314.9 | 314.25 |
Gross Profit | 59.86 | 74.64 | 81.43 | 188.07 | 253.31 | 207.45 |
Selling, General & Admin | 49.2 | 44.52 | 46.58 | 50.89 | 47.65 | 37.44 |
Research & Development | 33.97 | 35.8 | 40.62 | 40.7 | 41.37 | 28.51 |
Other Operating Expenses | 3.33 | 3.55 | 1.89 | 4.78 | 5.1 | 4.11 |
Operating Expenses | 84.96 | 82.33 | 90.59 | 95.18 | 94.54 | 70.41 |
Operating Income | -25.1 | -7.69 | -9.16 | 92.89 | 158.77 | 137.04 |
Interest Expense | -0.06 | -0.06 | -0.09 | -0.12 | -0.31 | -0.45 |
Interest & Investment Income | 47.73 | 39.37 | 46.94 | 28.96 | 8.2 | 4.62 |
Currency Exchange Gain (Loss) | -4.67 | -4.67 | 3.36 | 1.48 | 31.6 | -5.5 |
Other Non Operating Income (Expenses) | -9.41 | -0.31 | -0.2 | -0.19 | -0.09 | -0.27 |
EBT Excluding Unusual Items | 8.48 | 26.63 | 40.85 | 123.02 | 198.17 | 135.44 |
Gain (Loss) on Sale of Investments | 1.74 | 46.72 | -10.3 | 6.31 | -0.86 | 1.61 |
Gain (Loss) on Sale of Assets | -0.22 | -0.3 | -0.93 | -0.39 | - | - |
Asset Writedown | -5.59 | -1.66 | -14.36 | -3.97 | -1.85 | -1.11 |
Other Unusual Items | 3.45 | 3.45 | 2.95 | 3.58 | 7.01 | 2.49 |
Pretax Income | 7.88 | 74.85 | 18.21 | 128.54 | 202.46 | 138.44 |
Income Tax Expense | 1.28 | 10.55 | 1.81 | 16.36 | 25.15 | 18.24 |
Net Income | 6.6 | 64.29 | 16.41 | 112.18 | 177.31 | 120.2 |
Net Income to Common | 6.6 | 64.29 | 16.41 | 112.18 | 177.31 | 120.2 |
Net Income Growth | -88.97% | 291.89% | -85.38% | -36.73% | 47.51% | -14.78% |
Shares Outstanding (Basic) | 89 | 91 | 91 | 92 | 86 | 69 |
Shares Outstanding (Diluted) | 89 | 91 | 91 | 92 | 86 | 69 |
Shares Change | -1.25% | -0.65% | -0.88% | 6.83% | 25.31% | -0.17% |
EPS (Basic) | 0.07 | 0.71 | 0.18 | 1.22 | 2.06 | 1.75 |
EPS (Diluted) | 0.07 | 0.71 | 0.18 | 1.22 | 2.06 | 1.75 |
EPS Growth | -88.83% | 294.44% | -85.25% | -40.78% | 17.71% | -14.63% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -157.98 | -79.9 | -58.25 | 53.15 | 101.08 | 118.98 |
Free Cash Flow Per Share | -1.77 | -0.88 | -0.64 | 0.58 | 1.17 | 1.73 |
Dividend Per Share | 0.220 | 0.220 | 0.091 | 0.600 | 0.580 | 0.400 |
Dividend Growth | 141.76% | 141.76% | -84.83% | 3.45% | 45.00% | -42.86% |
Gross Margin | 15.18% | 17.25% | 18.96% | 38.44% | 44.58% | 39.77% |
Operating Margin | -6.37% | -1.78% | -2.13% | 18.98% | 27.94% | 26.27% |
Profit Margin | 1.67% | 14.86% | 3.82% | 22.93% | 31.20% | 23.04% |
Free Cash Flow Margin | -40.07% | -18.46% | -13.56% | 10.86% | 17.79% | 22.81% |
EBITDA | 22.35 | 39.23 | 39.24 | 148.89 | 210.37 | 183.15 |
EBITDA Margin | 5.67% | 9.07% | 9.14% | 30.43% | 37.02% | 35.11% |
D&A For EBITDA | 47.45 | 46.92 | 48.4 | 56 | 51.61 | 46.11 |
EBIT | -25.1 | -7.69 | -9.16 | 92.89 | 158.77 | 137.04 |
EBIT Margin | -6.37% | -1.78% | -2.13% | 18.98% | 27.94% | 26.27% |
Effective Tax Rate | 16.19% | 14.10% | 9.92% | 12.73% | 12.43% | 13.18% |
Revenue as Reported | 432.73 | 432.73 | 429.47 | 489.29 | 568.21 | 521.7 |
Advertising Expenses | - | - | - | - | 1.19 | - |